EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark LEXEO THERAPEUTICS was filed as Word mark on 04/04/2024 at the European Union Intellectual Property Office. The current status of the mark is "Application under examination".
| Trademark form | Word mark |
| File reference | 019009041 |
| Application date | April 4, 2024 |
Trademark owner
345 Park Avenue South, Sixth Floor
10010 New York, NY
US
10010 New York, NY
US
Trademark representatives
Harrlachweg 4
68163 Mannheim
DE
goods and services
5
Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Gene therapy for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Gene therapy for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects
ID: 11019009041